The study title: Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in Cardiogenic Shock.
The trial design : Prospective, open, multicentre, randomised strategy trial in Cardiogenic Shock.
We will test whether initiating, at a very early stage the use of a specific mechanical support device (MSD) namely (peripheral veno-arterial ECMO) to support the circulation at a very early stage, provides sufficient impact on organ perfusion whilst allowing any recoverable heart muscle to recover following revascularisation, and so beneficially alter prognosis. The recruitment target is 428 sites are activated.
All-cause mortality at 30 days
UK, Germany, Belgium, Spain, Norway, Latvia, Italy, Austria